Navigation Links
Neurogen Proprietary Insomnia Compound Data Presented at Associated,Professional Sleep Societies Annual Meeting

ts were enrolled (20 male and 12 female). Repeated daily dosing of NG2-73 did not result in accumulation and NG2-73 exhibited linear pharmacokinetics. The ability of NG2-73 to produce drowsiness and sleepiness was confirmed by the sedation assessment scores on the Stanford Sleepiness Scale and Visual Analog Scale in the multiple ascending dose study. In both studies the safety and tolerability of the compound were confirmed by the absence of serious adverse events, clinically significant laboratory findings, oxygen saturation level alterations, and electrocardiogram (ECG) abnormalities.

In these studies, NG2-73 was shown to be a novel sedative hypnotic which exhibited linear pharmacokinetics and was well tolerated up to 60 mg. This dosage is estimated to be 10- to 20-times the anticipated therapeutic dose.

About Neurogen

Neurogen Corporation is a drug discovery and development company focusing on small molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including insomnia, obesity, pain, Parkinson's disease, restless legs syndrome (RLS), and depression. Neurogen conducts its research and development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise.

Neurogen Safe Harbor Statement

The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws, which involve risks and uncertainties as detailed from time to time in Neurogen's SEC filings, including its most recent 10-K. Such forward-looking statements relate to activities, events or developments that Neurogen believes, expects or anticipates will occur in the future and include, but are not limited to, earnings estimates, statements that are not historical facts relating to Neurogen's future financial performance, its growth and business expansion, its financing plans, the timin
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Neurogen Announces Positive Results for Proprietary Insomnia Drug in Two Chronic Insomnia Clinical Trials
2. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
3. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
4. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
5. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
6. Modigene Announces Successful Completion of Pharmacokinetic & Pharmacodynamic Pre-Clinical Experiments for Proprietary Long-Acting Human Growth Hormone, Long-acting Interferon Beta and Long-acting Erythropoietin
7. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
8. Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR
9. Helix BioMedix to Discuss Potential of Its Proprietary Peptides at the BIO International Convention
10. Integrated Biopharmas Proprietary Vaccine Technology Achieves Strong Positive Results
11. Integrated BioPharmas Proprietary Vaccine Technology Achieves Strong Positive Results
Post Your Comments:
(Date:10/30/2014)... October 30, 2014 , Extensively ... cow milk   Cow milk protein allergy (CMPA) is the ... childhood. Until now, it has been managed by eliminating ... been shown that it is possible to help build ... number of children during the first year of life ...
(Date:10/30/2014)... nebulizer is a medical device used for the treatment ... converts liquid medication into mist or aerosol. Thus, the ... patient when inhaled through the mouth or a face ... devices powered by electric current and rechargeable batteries. Factors ... fibrosis and growing number of geriatric population worldwide support ...
(Date:10/30/2014)... Oct. 29, 2014   ViaDerma, Inc. ... bringing new products to market, is committed to ... has developed an innovative, patent-pending dual carrier transdermal ... of pharmaceutical active ingredients to penetrate the skin ... therapy. The transdermal delivery method also overcomes microbial ...
Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
... 1b study planned for mid 2008 with Phase 2 development ... to begin late in 2008 or in early ... NUVO ) today announced positive results from the Phase 1,proof-of-concept ... offset of anticoagulation after,a single bolus dose with a favorable safety ...
... Erythematosus ... ... (Nasdaq: RIGL ) announced today that its lead product,candidate, R788, ... reported in a recently published,study of the drug candidate. R788 (fostamatinib ...
Cached Medicine Technology:Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 2Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 3Nuvelo Announces Positive Proof-of-Concept Data With Anticogulant NU172 4Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 2Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 3Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies 4
(Date:10/30/2014)... Chicago, IL (PRWEB) October 30, 2014 Dr. ... launched a new website for his practices; OB GYN ... Chicago, IL . This website contains important information about ... covers as well as downloadable patient forms in English and ... use and the service pages on the website provide Dr. ...
(Date:10/30/2014)... Rock Hill, South Carolina (PRWEB) October 30, 2014 ... a muscle, and should be more vigorously exercised to ... Grewal. He recently authored the book ‘Dementia Express: Lose ... , The book uses counterintuitive reasoning and sometimes conflicting ... an obstacle course for the mind, a reader must ...
(Date:10/30/2014)... who used stem cells to create miniature human stomachs ... new way to learn more about the development and ... pluripotent stem cells -- which can become any type ... functional miniature stomachs, to study infection by H. ... stomach cancer. The miniature stomachs offer many research ...
(Date:10/30/2014)... WEDNESDAY, Oct. 29, 2014 (HealthDay News) -- Americans, opinions ... political lines, a new study finds. Democratic voters ... (ACA), according to the researchers. Almost three-quarters of Democrats ... ACA. Thirty percent want Congress to implement the current ... of the ACA. Among Independent voters, one-third want ...
(Date:10/29/2014)... women at first acted surprised. Some insisted the blood tests ... not used the study products assigned to them as participants ... likely consequence, did not find any of the three products ... were among 127 former VOICE participants who, as part of ... in in-depth interviews and/or focus group discussions after learning the ...
Breaking Medicine News(10 mins):Health News:Dr. Joseph Furlin Launches New Website with Information about Care Services 2Health News:‘Dementia Express’ Offers Contradictory and Sometimes Reverse Thinking, All to Keep its Reader on Their Toes With an Active Mind. 2Health News:Voters' Views on Obamacare Split Along Party Lines 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
... of hormone worsened respiratory disease , , THURSDAY, Nov. 20 ... may explain why women with cystic fibrosis tend to ... at the University of North Carolina report. , , ... 20 issue of the Journal of Clinical Investigation ...
... Reno,s Downtown Ballroom was transformed into a Cirque style extravaganza ... ballroom to help raise funds for one of Reno,s most ... residents and many of Nevada,s prominent leaders, including Nevada Governor ... To view the Multimedia News Release, go to: ...
... Nov. 20 Precyse Solutions, the leader in,driving ... management solutions, was recognized by the Eastern Technology,Council ... at the 16th,Enterprise Award Gala held at the ... top technology and life sciences companies and entrepreneurs. ...
... at risk for hospital visits of their own , , THURSDAY, ... for a loved one with Alzheimer,s results in 25 percent ... hospital visit every six months, says an Indiana University study. ... an Alzheimer,s patient is difficult, but the Indiana University researchers ...
... Quality Care , ARLINGTON HEIGHTS, Ill., Nov. 20 ... cannot afford to cut corners on quality of care, warns ... thing to temporarily substitute fillers for facelifts, ASPS says the ... professional training. This concern was discussed recently at the ASPS ...
... People are often reluctant to undergo a routine but ... be fatal. According to the American Cancer Society, colon ... American men and women and kills about 50,000 Americans ... cancer have no symptoms or family history," says Prof. ...
Cached Medicine News:Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 2Health News:Estrogen May Explain Why Women With Cystic Fibrosis Suffer More 3Health News:Photos: Nevada's Saint Mary's Regional Medical Center Raises $1.3 Million During Centennial Soiree 2Health News:Precyse Solutions Honored as 'Technology Company of the Year' 2Health News:When the Caregiver Becomes the Patient 2Health News:Caution Urged as Patients Seek Deals on Cosmetic Surgery 2Health News:A simple blood test for colon cancer 2
... Millipore has developed a range of ... match specific water quality requirements. Each ... is designed to specifically target contaminants ... HPLC, molecular biology and ICP-MS. The ...
Inquire...
... the Mo Bio Vortex Adapter in conjunction with ... procedures. Using the Mo Bio Vortex Adapter ... and Fast Prep machines which offer the same ... ml) centrifuge tubes at one time and will ...
... Combines BchiVac V-500 with Vacuum ... Efficiently controls vacuum levels from ... pump designed to handle most vacuum applications. ... up to two rotary evaporators Laboratory ...
Medicine Products: